Ann: PromarkerD kit version complete- commercial release imminent, page-35

piq floated at 20 cents a few years back. At that time prokarker D had not yet been developed, or proven. Patents had not been issued.  Our only source of revenue was the analytical stream, however we were not near cash flow positive.

Fast forward to today:

Prokarker D has been proven as the world's only test to accurately detect the onset of diabetic kidney disease up to 4 years in advance. Yesterday PIQ released the promarker test kit, which enables laboratories worldwide to roll out the test to patients with ease. Commercial Rollout of this test kit is imenent. 

Patents have been granted in major world markers for prokmarker D

Commercial deals have been signed in Latin America, usa and Spain for the right to use prokmarker D, with PIQ to receive royalties for each test conducted 

Our analytical sector is strong, with revenue from this stream alone nearing cash flow positive (when you remove r&d activities). This stream creates a great buffer, allowing us to continue with our R&D activities. 

Research into other biomarkers looks promising

we are sitting at 32.5 cents per share, and $26m market cap.

So perhaps knowing the above (and I'm sure I've missed a few things) id like you to ask yourself the question that you raised. 

CCheers,

Al